Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn Into More Strength?
JMP Securities Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $21
JMP Securities analyst Silvan Tuerkcan maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 38
Market Outperform: Relay Therapeutics Leads With Promising PI3K Inhibitor in Competitive Oncology Space
Relay Therapeutics Price Target Maintained With a $28.00/Share by Stifel
Stifel Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $28
Stifel analyst Bradley Canino maintains $Relay Therapeutics(RLAY.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 47.1% and
Relay up 5% as Street Applauds Breast Cancer Candidate Data